Furthermore, a subsequently diagnosed high-grade ovarian cancer is currently successfully undergoing targeted therapy with PARP-inhibitor olaparib, based on genetic testing results revealing interstitial loss harboring BRCA2. The gene discussed is BRCA2; the disease is ovarian carcinoma.